

## COMMUNICATION

November 26<sup>th</sup>, 2024

SUBSTIPHARM, Paris, France

### **Substipharm acquires exclusive rights to Evista® in select territories from Lilly**

**SUBSTIPHARM**, a French-based global pharmaceutical company, announced that it has acquired the rights for Evista® in Japan, Mexico, USA, Australia, and Brazil from **ELI LILLY AND COMPANY**, the global pharmaceutical company headquartered in Indianapolis, Indiana, USA.

SUBSTIPHARM already manufactures and holds marketing authorizations in Europe for Evista® and adding more territories outside Europe further consolidates the company's international portfolio.

Evista® is a renowned brand containing the active ingredient "raloxifene" and is indicated for the treatment and prevention of osteoporosis in postmenopausal women and reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis, where applicable for each market.

SUBSTIPHARM is a global pharmaceutical company focused on developing, manufacturing, and marketing various products both in retail and hospitals in various geographies around the world.